Singapore Summit Capital invests in early-stage Science Technology companies in the therapeutic, medical technology diagnostics and computer tech fields. Our geographical scope is Asia with particular emphasis on China, South East Asia and India.
Our point of entry differs depending on the type of the Science tech opportunity. In the therapeutic field, we invest when drug candidates are in the pre-clinical or clinical phase I. In the areas of medical technology and diagnostics, we tend to invest in companies just before the pivotal clinical trials require supporting the intended use and marketing affirmations. In the computer Science field we are already invested in projects that will be on the cutting edge of computing software and hardware developments, that over all will enhance consumer demands for potential technological advances.
Singapore Summit Capital Management investment strategy has a strong industry focus on potential buyers of our portfolio companies. Since we believe that most exits in the Life and technology Science communities will continue to take place in the developmental Prime stages, we prefer business models suitable for this exit route. To appear on potential acquirers’ alert screens, we invest in opportunities that have the potential of becoming either a threat or a complement to existing products on the market. We look out for opportunities, which target unmet medical and technology needs in commercially attractive markets, and we seek products, which, once approved, are likely to receive attractive reimbursement and pricing structures. We have a preference for companies targeting niche markets. In the therapeutic area, opportunities aimed at specialty pharmaceuticals and orphan drug indications are especially lucrative, as well being on the cusp of merging and developing computer software applications, and keeping up to date with the next generation in computer hardware development as technology in this field continues to expand and grow to excel our current expectations on their performances.
We believe that the single most important factor when developing a successful company is the quality of the management team. This is not the same as saying that we only invest in clever and shrewd entrepreneurs with a strong track record. But our stringent thorough research in such ventures is our strength in determining the success story’s for the many clients we already represent.